中西医结合肝病杂志
中西醫結閤肝病雜誌
중서의결합간병잡지
CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE ON LIVER DISEASES
2014年
5期
270-272
,共3页
肝炎, 乙型, 慢性%肝纤维化%六味五灵片/治疗应用%替比夫定/治疗应用
肝炎, 乙型, 慢性%肝纖維化%六味五靈片/治療應用%替比伕定/治療應用
간염, 을형, 만성%간섬유화%륙미오령편/치료응용%체비부정/치료응용
chronic hepatitis B%fibrosis%Liuweiwuling tablets/therapeutic application%telbivudine/therapeutic applica-tion
目的:观察六味五灵片联合替比夫定( LdT)治疗慢性乙型肝炎( CHB)肝纤维化的临床疗效。方法:将120例CHB肝纤维化患者随机分为观察组和对照组。观察组(64例)患者口服六味五灵片和LdT,对照组(56例)患者单用LdT,疗程均为24周。比较两组患者治疗前后的临床症状、肝功能及肝纤维化指标变化情况。结果:治疗24周后,观察组患者ALT、 AST、 TBil分别为(25.4±16.3) U/L、(28.4±15.9) U/L、(22.8±10.7)μmol/L,均明显低于对照组(44.7±19.6) U/L、(40.1±17.1) U/L、(35.2±11.5)μmol/L ,差异有显著性意义( P<0.05)。治疗后两组患者肝纤维化指标均显著下降,且观察组下降幅度优于对照组(P<0.05)。结论:六味五灵片联合LdT能够明显改善CHB肝纤维化患者的肝功能,促进HBV DNA转阴,同时还能显著降低患者的血清肝纤维化指标,提高临床疗效。
目的:觀察六味五靈片聯閤替比伕定( LdT)治療慢性乙型肝炎( CHB)肝纖維化的臨床療效。方法:將120例CHB肝纖維化患者隨機分為觀察組和對照組。觀察組(64例)患者口服六味五靈片和LdT,對照組(56例)患者單用LdT,療程均為24週。比較兩組患者治療前後的臨床癥狀、肝功能及肝纖維化指標變化情況。結果:治療24週後,觀察組患者ALT、 AST、 TBil分彆為(25.4±16.3) U/L、(28.4±15.9) U/L、(22.8±10.7)μmol/L,均明顯低于對照組(44.7±19.6) U/L、(40.1±17.1) U/L、(35.2±11.5)μmol/L ,差異有顯著性意義( P<0.05)。治療後兩組患者肝纖維化指標均顯著下降,且觀察組下降幅度優于對照組(P<0.05)。結論:六味五靈片聯閤LdT能夠明顯改善CHB肝纖維化患者的肝功能,促進HBV DNA轉陰,同時還能顯著降低患者的血清肝纖維化指標,提高臨床療效。
목적:관찰륙미오령편연합체비부정( LdT)치료만성을형간염( CHB)간섬유화적림상료효。방법:장120례CHB간섬유화환자수궤분위관찰조화대조조。관찰조(64례)환자구복륙미오령편화LdT,대조조(56례)환자단용LdT,료정균위24주。비교량조환자치료전후적림상증상、간공능급간섬유화지표변화정황。결과:치료24주후,관찰조환자ALT、 AST、 TBil분별위(25.4±16.3) U/L、(28.4±15.9) U/L、(22.8±10.7)μmol/L,균명현저우대조조(44.7±19.6) U/L、(40.1±17.1) U/L、(35.2±11.5)μmol/L ,차이유현저성의의( P<0.05)。치료후량조환자간섬유화지표균현저하강,차관찰조하강폭도우우대조조(P<0.05)。결론:륙미오령편연합LdT능구명현개선CHB간섬유화환자적간공능,촉진HBV DNA전음,동시환능현저강저환자적혈청간섬유화지표,제고림상료효。
Objective: To observe the clinical effect of Liuweiwuling tablets combined with telbivudine in treatment of hepa-titis B liver fibrosis.Methods: One hundred and twenty cases of chronic hepatitis B ( CHB) patients with fibrosis were randomly divided into two groups:the observation group and the control group.The observation group of 64 cases received Liuweiwuling tablets and oral telbivudine;the control group of 56 cases received simple oral telbivudine.The changes of clinical symptoms, liver function and index hepatic fibrosis of the two groups were observed before and after treatment.Results: After 24 weeks′treatment, the value of ALT, AST and TBil of the observation group [respectively, (25.4 ±16.3) U/L, (28.4 ±15.9) U/L, (22.8 ±10.7) μmol/L] were all lower than the control group [respectively, (44.7 ±19.6) U/L, (40.1 ±17.1) U/L, (35.2 ±11.5) μmol/L, P<0.05] and the difference was statistically significant (P<0.05) .And the index hepatic fibrosis of both groups was all reduced after treatment, while the reduction of the observation group was significantly higher than the con-trol group.Conclusion: The therapy of Liuweiwuling tablets combined with telbivudine in treatment of CHB fibrosis can improve liver function and promote negative conversion of HBV DNA, meanwhile, it can also decrease the serum liver fibrosis indexes and increase the treatment effect.